Tenax Therapeutics Inc.'s (TENX) phase II trial, which evaluated Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, has produced mixed results.
from RTT - Biotech https://ift.tt/36XtxCK
via IFTTT
No comments:
Post a Comment